About Sutro Biopharma

Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Learn More


Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency.

Learn More


Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways.

Learn More

Recent News


Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments

STRO-002 Initial Safety Data from an Ongoing Phase 1 Trial in Ovarian and Endometrial Cancers presented at the AACR-NCI-EORTC Molecular Targets and Cancer.. Read More →

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster Antitumor activity of STRO-002, a novel anti-folate receptor -⍺ (FolR⍺) antibody drug conjugate.. Read More →


At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference both as individuals and as part of a team.

Learn More